Newsbenzinga
Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce
· Published
Article summary
Novo Nordisk targets 2026-2030 growth, and unveils Phase 3 CagriSema results beating Eli Lilly's tirzepatide in weight loss trials.
An excerpt from the original article.
Comments —
Loading comments…